Though oncology is the top priority for OSI, research and development targeting type 2 diabetes and obesity is conducted through their U.K. subsidiary Prosidion Limited.
Meskipun onkologi merupakan prioritas utama bagi OSI, penelitian dan pengembangan menargetkan diabetes melitus tipe 2 dan obesitas dilakukan melalui anak perusahaan Britania Raya mereka Prosidion Limited.